BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24351969)

  • 1. Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
    Legault G; Kieran MW; Scott RM; Chordas C; Milla SS; Karajannis MA
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e533-5. PubMed ID: 24351969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.
    Karajannis MA; Legault G; Fisher MJ; Milla SS; Cohen KJ; Wisoff JH; Harter DH; Goldberg JD; Hochman T; Merkelson A; Bloom MC; Sievert AJ; Resnick AC; Dhall G; Jones DT; Korshunov A; Pfister SM; Eberhart CG; Zagzag D; Allen JC
    Neuro Oncol; 2014 Oct; 16(10):1408-16. PubMed ID: 24803676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI capture of intermittent ventriculomegaly in a patient with ventriculo-peritoneal shunt.
    Aly A; El-Beshlawi I; Howarth S; Smith S
    Br J Neurosurg; 2017 Oct; 31(5):601-602. PubMed ID: 28574289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hand-foot-skin reaction related to use of the multikinase inhibitor sorafenib and hard orthotics.
    Kusari A; Borok J; Han AM; Valderrama AJ; Friedlander SF
    Pediatr Dermatol; 2018 Jul; 35(4):e206-e209. PubMed ID: 29766555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular characteristics of pediatric low-grade glioma complicated with ventriculo-peritoneal shunt related ascites.
    Solano-Páez P; Fonseca A; Baroni LV; Amayiri N; Somarriba MP; Freytes C; Quiroga E; Rivero M; Márquez J; Lassaletta Á; Bouffet E
    J Neurooncol; 2022 Mar; 157(1):147-156. PubMed ID: 35122583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptomeningeal dissemination of pilocytic astrocytoma in a 17-year-old boy.
    Jandaghi AB; Bidabadi E; Saadat S; Alijani B; Daliri S; Reyhanian Z; Mashouf M
    Turk Neurosurg; 2014; 24(6):978-81. PubMed ID: 25448220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced cerebrospinal fluid malabsorption in a shunted child: case report and review of the literature.
    O'Halloran PJ; Kaliaperumal C; Caird J
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23396932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain metastases as a cause of malignant cerebrospinal fluid ascites: case report and review of the literature.
    Low YY; Thomas J; Wan WK; Ng WH
    CNS Oncol; 2012 Sep; 1(1):29-37. PubMed ID: 25054298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peritoneal seeding of a cerebral malignant astrocytoma via a ventriculo-peritoneal shunt.
    Declercq H; De Man R; Vanderperre H; De Praetere P; Wilms G
    J Belge Radiol; 1992 Jun; 75(3):191-3. PubMed ID: 1400149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
    Schneider TC; Kapiteijn E; van Wezel T; Smit JWA; van der Hoeven JJM; Morreau H
    BMC Cancer; 2016 Jan; 16():31. PubMed ID: 26786320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.
    Hassler MR; Ackerl M; Flechl B; Sax C; Wöhrer A; Widhalm G; Dieckmann K; Hainfellner J; Preusser M; Marosi C
    Anticancer Drugs; 2014 Jul; 25(6):723-8. PubMed ID: 24441743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation recall dermatitis induced by sorafenib : A case study and review of the literature.
    Stieb S; Riesterer O; Brüssow C; Pestalozzi B; Guckenberger M; Weiler S
    Strahlenther Onkol; 2016 May; 192(5):342-8. PubMed ID: 26907093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
    Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
    Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
    Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A
    Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.
    Sie M; den Dunnen WF; Lourens HJ; Meeuwsen-de Boer TG; Scherpen FJ; Zomerman WW; Kampen KR; Hoving EW; de Bont ES
    PLoS One; 2015; 10(3):e0122555. PubMed ID: 25799134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients.
    Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
    Am J Ther; 2017; 24(1):e81-e101. PubMed ID: 26322676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.